 In the first cycle, study participants will be randomly assigned to either placebo or COQ10 capsules, AOR - Advanced Orthomolecular Research Inc. 19 St NE Calgary, Alberta, NHPD registration codes 135307 and 113519, respectively. Study participants will take 600 mg of CoQ10 orally or identical placebo capsules for up to 5 cycles if pregnancy does not occur. All subjects will commence controlled ovarian stimulation COH using highly purified human menopausal gonadotropins Menopur; Ferring Inc., North York,Ontario Canada. The starting dosage of Menopur will range from 75IU to 250 IU daily S.C. will be determined by the physician and will begin on the third day of menses, and will continue until the day prior to human chorionic gonadotropin hCG administration. The dosage will not be changed and must be maintained for the duration of the study. Menopur will continue daily until follicular development is considered adequate. at least 1 follicle is 17 mm, and the E2 level is acceptable for the number of follicles present. The patient will receive an injection of hCG 250 mcg Ovidrel, EMD Serono,Oakville, Ontario, Canada , SC for the final stage of follicular maturation. Insemination will be by intrauterine insemination IUI. Luteal support will consist of progesterone suppositiories 200mg Kingsway Pharmacy,Toronto, Ontario Canada vaginally per day starting on the day of IUI and will continue for 2 weeks until the serum beta hCG result. At the end of each cycle serum beta hCG will be drawn and if women are pregnant CoQ10 placebo will be discontinued. If pregnant, luteal support will continue until 10 weeks gestation. If the patient is not pregnant she will have a cycle off COH but may attempt to conceive naturally. In the third cycle, COH using the same dose of Menopur as in the first cycle will be performed with IUI as in cycle one. If not pregnant, another cycle off treatment will be followed by the fifth cycle in which COH and IUI is performed.. 